Green Thumb Industries Inc. (CSE:GTII) Shares Could Be 43% Below Their Intrinsic Value Estimate
Dec 05
Have your own idea? Try our Stock Screener
Canadian (TSX) Pharma Industry Analysis
UpdatedDec 08, 2025
DataAggregated Company Financials
Companies58
- 7D5.4%
- 3M-11.9%
- 1Y-5.5%
- YTDn/a
In the last week, the Pharma industry is up 5.4%, with Curaleaf Holdings up 12%. Meanwhile, Vireo Growth actually underperformed within the industry, shrinking 8.8% in the last week. In the past year, the industry is down 5.5%. As for the next few years, earnings are expected to grow by 62% per annum.
Industry Valuation and Performance
Has the Canadian Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 08 Dec 2025 | CA$14.3b | CA$11.3b | -CA$1,917,133,404.86 | 14.4x | -7.5x | 1.3x |
| Wed, 05 Nov 2025 | CA$15.8b | CA$11.3b | -CA$2,048,944,554.26 | 31.3x | -7.7x | 1.4x |
| Fri, 03 Oct 2025 | CA$17.4b | CA$11.2b | -CA$2,035,948,891.58 | 40.1x | -8.5x | 1.5x |
| Sun, 31 Aug 2025 | CA$18.1b | CA$11.8b | -CA$2,512,553,770.67 | 39.9x | -7.2x | 1.5x |
| Tue, 29 Jul 2025 | CA$11.8b | CA$11.8b | -CA$2,539,661,561.55 | 17.1x | -4.6x | 1x |
| Thu, 26 Jun 2025 | CA$9.5b | CA$11.7b | -CA$2,523,241,308.82 | 16.8x | -3.8x | 0.8x |
| Sat, 24 May 2025 | CA$23.8b | CA$11.8b | -CA$2,386,824,912.03 | 17.8x | -10x | 2x |
| Mon, 21 Apr 2025 | CA$9.7b | CA$12.0b | -CA$2,565,498,718.65 | 19.1x | -3.8x | 0.8x |
| Wed, 19 Mar 2025 | CA$10.7b | CA$12.3b | -CA$2,640,199,995.40 | 19.1x | -4.1x | 0.9x |
| Fri, 14 Feb 2025 | CA$12.4b | CA$12.1b | -CA$2,212,969,547.00 | 23.8x | -5.6x | 1x |
| Sun, 12 Jan 2025 | CA$12.4b | CA$12.2b | -CA$2,417,209,526.77 | 28.7x | -5.1x | 1x |
| Tue, 10 Dec 2024 | CA$13.6b | CA$12.0b | -CA$2,581,746,931.12 | 23x | -5.3x | 1.1x |
| Thu, 07 Nov 2024 | CA$19.1b | CA$11.9b | -CA$2,771,044,784.66 | 18x | -6.9x | 1.6x |
| Sat, 05 Oct 2024 | CA$18.6b | CA$11.6b | -CA$2,680,134,100.30 | 27.4x | -6.9x | 1.6x |
| Mon, 02 Sep 2024 | CA$17.1b | CA$11.6b | -CA$2,690,218,404.94 | 20.2x | -6.4x | 1.5x |
| Wed, 31 Jul 2024 | CA$20.1b | CA$11.8b | -CA$3,212,184,320.34 | 20x | -6.2x | 1.7x |
| Fri, 28 Jun 2024 | CA$20.4b | CA$11.8b | -CA$3,239,151,617.43 | 18.8x | -6.3x | 1.7x |
| Sun, 26 May 2024 | CA$21.8b | CA$11.9b | -CA$3,490,501,699.08 | 12.8x | -6.2x | 1.8x |
| Tue, 23 Apr 2024 | CA$23.2b | CA$12.0b | -CA$3,476,028,729.95 | 8.2x | -6.7x | 1.9x |
| Thu, 21 Mar 2024 | CA$22.6b | CA$11.8b | -CA$3,477,097,457.18 | 9.5x | -6.5x | 1.9x |
| Sat, 17 Feb 2024 | CA$22.3b | CA$12.0b | -CA$4,643,332,391.61 | 10.4x | -4.8x | 1.9x |
| Mon, 15 Jan 2024 | CA$20.3b | CA$12.3b | -CA$6,744,251,485.00 | 9.3x | -3x | 1.7x |
| Wed, 13 Dec 2023 | CA$17.3b | CA$12.4b | -CA$6,782,848,879.00 | 8.2x | -2.6x | 1.4x |
| Fri, 10 Nov 2023 | CA$16.9b | CA$12.5b | -CA$7,314,992,422.00 | 10.3x | -2.3x | 1.4x |
| Sun, 08 Oct 2023 | CA$18.6b | CA$12.4b | -CA$7,334,632,248.00 | 15x | -2.5x | 1.5x |
| Tue, 05 Sep 2023 | CA$18.0b | CA$13.0b | -CA$7,911,625,052.00 | 13.3x | -2.3x | 1.4x |
| Thu, 03 Aug 2023 | CA$15.2b | CA$13.3b | -CA$9,743,091,053.00 | 12.1x | -1.6x | 1.1x |
| Sat, 01 Jul 2023 | CA$14.8b | CA$13.2b | -CA$9,514,993,365.00 | 11.4x | -1.6x | 1.1x |
| Mon, 29 May 2023 | CA$14.9b | CA$13.4b | -CA$10,471,665,836.00 | 10.2x | -1.4x | 1.1x |
| Wed, 26 Apr 2023 | CA$14.9b | CA$13.5b | -CA$9,997,376,351.00 | 10.8x | -1.5x | 1.1x |
| Fri, 24 Mar 2023 | CA$17.2b | CA$13.8b | -CA$10,095,082,425.00 | 9.1x | -1.7x | 1.2x |
| Sun, 19 Feb 2023 | CA$20.4b | CA$13.6b | -CA$10,307,884,782.00 | 10.5x | -2x | 1.5x |
| Tue, 17 Jan 2023 | CA$20.9b | CA$13.5b | -CA$10,099,014,878.00 | 13.4x | -2.1x | 1.5x |
| Thu, 15 Dec 2022 | CA$23.4b | CA$13.6b | -CA$10,200,923,205.00 | 15.9x | -2.3x | 1.7x |
Price to Earnings Ratio
-2.3x
Current Industry PE
- Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
- Meanwhile revenues for these companies have declined 6.2% per year.
- This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.
Industry Comparison
How does Canadian Pharma compare with similar industries?
| CA Market | -0.19% | |
| Healthcare | 2.74% | |
| Pharma | 5.43% | |
| Pharma | 5.43% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| CURA Curaleaf Holdings | CA$3.79 | 11.8% +CA$308.9m | 50.4% | PS1.7x | |
| IAN iAnthus Capital Holdings | CA$0.01 | 100.0% +CA$34.1m | 100.0% | PE29.3x | |
| GTII Green Thumb Industries | CA$9.19 | 1.3% +CA$27.8m | -23.5% | PE35.3x | |
| MTLC MTL Cannabis | CA$0.50 | 38.9% +CA$16.8m | 163.2% | PS0.7x | |
| CRDL Cardiol Therapeutics | CA$1.43 | 10.9% +CA$13.8m | -31.6% | PB14.8x |
